Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company Plc (NYSE: PRGO) is a global provider of quality, affordable self-care products and over-the-counter health solutions. This dedicated news hub offers investors and industry professionals centralized access to official announcements, financial disclosures, and market developments.
Track Perrigo's strategic initiatives through verified press releases covering earnings results, product innovations, regulatory milestones, and partnership announcements. Our curated collection provides essential insights into the company's operations across key markets in North America, Europe, and global consumer health sectors.
Discover updates on Perrigo's store-brand leadership, branded OTC developments, and manufacturing advancements. The resource serves as a reliable reference for monitoring the company's progress in delivering accessible healthcare solutions through major retail partnerships and direct-to-consumer channels.
Bookmark this page for streamlined access to Perrigo's latest business updates, including analysis of market positioning in consumer self-care categories and operational efficiency programs. Stay informed about one of the OTC sector's most established innovators through verified, up-to-date information sources.
Perrigo Company plc (NYSE; TASE: PRGO) announced a voluntary recall of albuterol sulfate inhalation aerosol due to clogging complaints. This follows the halting of production and distribution. The recall is part of corrective actions, but a timeline for reintroduction is not set. The company anticipates a charge of approximately $18 million to $22 million in Q3 2020 but maintains its fiscal year 2020 adjusted EPS guidance of $3.95 to $4.15, attributing stability to strong consumer demand in its self-care segments. Sales of the inhalation aerosol ceased in late August 2020.
Perrigo's Steripod brand highlights the importance of maintaining oral health as schools reopen amid COVID-19. They advocate for regular toothbrush replacement every 90 days, as recommended by the ADA, to combat airborne illnesses. Greg McCormick, Senior VP of Global Innovation and Technology, emphasizes the need for protecting toothbrushes from contaminants. Key tips include replacing brushes during illness and using Steripod protectors. Perrigo's dedication to quality self-care products is underscored, with a focus on empowering consumers to manage their health proactively.
Perrigo Company plc (NYSE: PRGO) announced the launch of its store brand equivalent of Voltaren Arthritis Pain, now available nationwide in the U.S. This topical gel, containing diclofenac sodium 1%, is the first store brand ANDA approved by the FDA for OTC use. Previously, generic prescription sales of Voltaren exceeded $250 million annually. The launch highlights Perrigo's OTC self-care platform, aimed at providing high-quality alternatives in self-care categories.
Perrigo Company (NYSE; TASE: PRGO) announced its participation in the Barclay's Global Consumer Staples Conference on September 9, 2020, with CEO Murray S. Kessler and CFO Ray Silcock hosting virtual one-on-one meetings.
Additionally, Kessler is set to present at the 18th Annual Morgan Stanley Global Healthcare Conference on September 17, 2020, at 8:45 am EST. The presentation will be accessible via a webcast on Perrigo's investor relations site.
Perrigo Company plc (NYSE: PRGO) has announced the acquisition of three OTC skincare and hair loss treatment brands—Emolium®, Iwostin®, and Loxon®—from Sanofi for approximately €21 million ($23 million). This strategic move aims to enhance Perrigo's self-care portfolio and strengthen its presence in the Eastern European market. The transaction, expected to close in Q4 2020, aligns with Perrigo's growth strategy focused on margin enhancement and market expansion. CEO Murray S. Kessler emphasized this acquisition will deliver shareholder value and bolster their product offerings.
Perrigo Company plc (PRGO) reported a strong performance in Q2 2020, with consolidated net sales of $1.2 billion, up 6.1% year-over-year. Adjusted diluted EPS rose 19.8% to $1.03. The company reaffirmed its fiscal 2020 outlook, projecting net sales growth of 6% to 7% and adjusted EPS between $3.95 and $4.15, despite challenges from COVID-19 costs. Consumer Self-Care Americas net sales increased 7.8% to $628 million, driven by e-commerce growth and strong demand for essential products.
Perrigo Company plc (NYSE; TASE: PRGO) has declared a quarterly dividend of $0.225 per share, with payment scheduled for September 15, 2020. Shareholders on record as of August 28, 2020 will receive this dividend.
The company aims to enhance individual well-being by providing Quality, Affordable Self-Care Products that consumers trust. This announcement reflects Perrigo's commitment to returning value to its shareholders.
Perrigo Company plc (NYSE; TASE: PRGO) will announce its second quarter financial results on August 5, 2020, with a conference call scheduled for 9:00 a.m. (EDT). Interested investors can access the call via webcast on Perrigo's investor relations website or by phone. A replay will be available from 12:00 p.m. (EDT) on the same day until midnight on August 12, 2020. The company focuses on providing affordable self-care products, enhancing the well-being of consumers, and is dedicated to transparency regarding future financial performance and associated risks.
Perrigo Company plc (NYSE: PRGO) has successfully closed a public offering of $750 million in 3.150% Senior Notes due 2030. The offering aims to collect approximately $737.1 million in net proceeds after expenses. Perrigo plans to utilize these proceeds primarily to redeem existing 3.500% Senior Notes due in 2021 and for other corporate purposes. The offering was managed by BofA Securities, J.P. Morgan, and Wells Fargo Securities.
Perrigo Company plc has finalized an agreement to sell its U.K.-based Rosemont Pharmaceuticals for £156 million, approximately $195 million, to a private equity firm. This deal marks a key step in Perrigo's strategy to transition to a consumer-focused self-care company. In 2019, Rosemont generated net sales of $53 million and contributed $0.12 to adjusted diluted EPS. CEO Murray S. Kessler emphasized the successful divestiture at an attractive tenfold adjusted operating income multiple, demonstrating commitment to shareholder value.
